Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals, Inc.) completed a merger with Legacy Palvella Therapeutics, Inc. on December 13, 2024, shifting its focus to developing therapies for rare skin diseases and vascular malformations. The company's lead product candidate, QTORIN rapamycin, is in clinical development for microcystic lymphatic malformations (LMs) and cutaneous venous malformations (VMs). In February 2026, Palvella announced positive topline results from a Phase 3 trial of QTORIN rapamycin for microcystic LMs, meeting the primary endpoint with a statistically significant improvement. The company also reported positive topline efficacy results from a Phase 2 trial of QTORIN rapamycin for cutaneous VMs in December 2025.
The company's operating loss for the year ended December 31, 2025, was $38.6 million, compared to $14.1 million for the year ended December 31, 2024. Research and development expenses increased to $22.8 million in 2025 from $8.2 million in 2024, driven by increased spending on clinical development of QTORIN rapamycin. General and administrative expenses also rose to $15.8 million in 2025 from $5.9 million in 2024, primarily due to increased headcount and professional service fees associated with operating as a public company. Palvella has never generated revenue from product sales.
Palvella's cash and cash equivalents as of December 31, 2025, totaled $58.0 million. In February 2026, the company completed a public offering of common stock, generating net proceeds of approximately $215.8 million. Palvella anticipates that its existing cash and cash equivalents, along with the proceeds from the public offering, will be sufficient to fund its planned operations for at least the next twelve months. The company's future capital requirements will depend on various factors, including the progress of its clinical trials, regulatory approvals, and potential commercialization activities.
Strategic developments include the expansion of the QTORIN rapamycin program into clinically significant angiokeratomas and the introduction of a new product candidate, QTORIN pitavastatin, for disseminated superficial actinic porokeratosis (DSAP). Palvella plans to initiate a Phase 2 study for QTORIN rapamycin in angiokeratomas and a Phase 2 study for QTORIN pitavastatin in DSAP in the second half of 2026. The company has received Fast Track Designation for QTORIN rapamycin for the treatment of microcystic LM, cutaneous VMs, and angiokeratomas, as well as Breakthrough Therapy Designation for microcystic LM. Palvella submitted a pre-NDA meeting request to the FDA in the first quarter of 2026 and anticipates the meeting to occur during the second quarter of 2026.
About PALVELLA THERAPEUTICS, INC.
Palvella Therapeutics develops topical, targeted therapies for serious, rare genetic skin diseases. Its lead product, QTORIN rapamycin, aims to treat microcystic lymphatic malformations and venous malformations by delivering rapamycin directly to affected skin layers, minimizing systemic side effects. The company leverages its proprietary QTORIN platform, focusing on unmet medical needs, innovative formulations, and strategic collaborations to become a leader in rare dermatologic conditions.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.